Novartis exercised its right to acquire Selexys Pharmaceuticals (held since 2012 option) for ~$665M total consideration following positive Phase 2 SUSTAIN data. Lead asset SelG1, an anti-P-selectin antibody for vaso-occlusive crises in sickle cell disease. Approved as Adakveo (crizanlizumab) in November 2019 (subsequently withdrawn EU 2023 after Phase 3 failure).
Did it work? Outcome assessment
Strategic verdict
Partially Achieved
Financial impact
Dilutive
Pipeline outcome
Assets Advanced
Assessment window: 5yr post-close.
Key facts
AnnouncedOct 25, 2016
ClosedDec 19, 2016
Deal value$665M
Deal typeAcquisition/Merger
Therapeutic areaVaso-occlusive pain crises in sickle cell disease (SCD)
IndicationsVaso-occlusive pain crises in sickle cell disease (SCD)